Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
$0.71
-1.1%
$4.97
$0.24
$1.49
$10.56M2.82127,174 shs82,490 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$4.62
+0.9%
$4.33
$3.62
$9.18
$33.46M0.653,086 shs409,439 shs
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$0.05
+9.4%
$0.07
$0.03
$10.79
$280K1.4249.82 million shs151.28 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.57
$4.82
$18.75
$97.22M-0.8863,472 shsN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$16.88
+1.0%
$17.15
$12.12
$26.99
$53.38M0.5822,685 shs2,192 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
0.00%+10.82%-1.93%-60.98%-85.64%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
+1.55%+0.66%-0.22%+11.44%-28.09%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-8.57%-8.02%-60.05%-94.63%-98.54%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%+4.46%-49.61%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-1.76%+10.70%+8.09%-10.06%-25.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
4.024 of 5 stars
3.22.00.04.62.22.50.6
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
3.2008 of 5 stars
3.33.00.00.02.92.51.3
OptiNose, Inc. stock logo
OPTN
OptiNose
0.6657 of 5 stars
1.00.00.04.20.61.70.6
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.6184 of 5 stars
3.52.00.00.02.70.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
0.00
N/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$39.50754.98% Upside
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.50
Moderate Buy$25.0049,700.80% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
2.00
Hold$9.00-6.25% Downside
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
3.00
Buy$35.50110.31% Upside

Current Analyst Ratings Breakdown

Latest NCNA, KZR, VTVT, OPTN, and GEMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A$0.54 per shareN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.82N/AN/A$16.02 per share0.29
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$1.34 per shareN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
$81.86M1.19N/AN/A($11.56) per share-0.83
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$1.02M52.79N/AN/A$4.48 per share3.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-$23.64MN/A0.00N/AN/A-419.70%-173.05%N/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$18.46M-$3.01N/AN/AN/A-121.46%-46.75%8/6/2025 (Estimated)

Latest NCNA, KZR, VTVT, OPTN, and GEMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.25N/AN/AN/AN/AN/A
6/2/2025Q1 2025
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$0.0129-$0.63-$0.6171-$0.63N/AN/A
5/15/2025Q1 2025
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$0.73-$0.77-$0.04-$0.77N/AN/A
5/13/2025Q1 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.56-$2.27+$0.29-$2.27N/AN/A
5/13/2025Q1 2025
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/A
0.67
0.67
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.04
7.09
7.09
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
1.25
1.25
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.79
0.72
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
7.39
7.39

Institutional Ownership

CompanyInstitutional Ownership
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
17.53%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
22.70%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
9.30%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
31.20%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.30%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
1.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
914.87 millionN/ANot Optionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.31 million6.63 millionNot Optionable
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
306.08 million4.18 millionNot Optionable
OptiNose, Inc. stock logo
OPTN
OptiNose
19010.13 million9.83 millionNot Optionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
93.19 million3.15 millionNot Optionable

Recent News About These Companies

vTv resumes Phase III oral T1D drug study
vTv Therapeutics initiated with a Buy at H.C. Wainwright
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
vTv Therapeutics stock surges on FDA update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gemphire Therapeutics stock logo

Gemphire Therapeutics NASDAQ:GEMP

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$4.62 +0.04 (+0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$4.72 +0.10 (+2.16%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

NuCana stock logo

NuCana NASDAQ:NCNA

$0.05 +0.00 (+9.37%)
Closing price 04:00 PM Eastern
Extended Trading
$0.05 0.00 (-1.39%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

OptiNose stock logo

OptiNose NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$16.88 +0.17 (+1.02%)
Closing price 03:49 PM Eastern
Extended Trading
$16.80 -0.08 (-0.50%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.